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Abstract
Background: Dementia is increasing in prevalence as the population ages. An earlier rather than later diagnosis
allows persons with dementia and their families to plan ahead and access appropriate management. However,
most diagnoses are made by general practitioners (GPs) later in the course of the disease and are associated with
management that is poorly adherent to recommended guidelines. This trial examines the effectiveness of a peer
led dementia educational intervention for GPs.
Methods: The study is a cluster randomised trial, conducted across three states and five sites. All GPs will
complete an audit of their consenting patients aged 75 years or more at three time points - baseline, 12 and 24
months. GPs allocated to the intervention group will receive two educational sessions from a peer GP or nurse,
and will administer the GPCOG to consenting patients at baseline and 12 months. The first education session will
provide information about dementia and the second will provide individualised feedback on audit results. GPs in
the waitlist group will receive the RACGP Guidelines by post following the 12 month audit
Outcomes: Primary outcomes are carer and consumer quality of life and depression. Secondary outcomes include:
rates of GP identification of dementia compared to a more detailed gold standard assessment conducted in the
patient’s home; GP identification of differential diagnoses including reversible causes of cognitive impairment; and
GP referral to specialists, Alzheimers’ Australia and support services. A “case finding” and a “screening” group will be
compared and the psychometrics of the GPCOG will be examined.
Sample size: Approximately 2,000 subjects aged 75 years and over will be recruited through approximately 160
GPs, to yield approximately 200 subjects with dementia (reducing to 168 by 24 months).
Discussion: The trial outlined in this paper has been peer reviewed and supported by the Australian National
Health and Medical Research Council. At the time of submission of this paper 2,034 subjects have been recruited
and the intervention delivered to 114 GPs.
Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12607000117415.
Background
Importance of dementia as an issue
Dementia is an increasingly common condition largely
due to increasing longevity of the population in
Australia, and other countries. Approximately 1 in 5
Australians over the age of 80 have some form of
dementia [1]. By 2050 the number of adults 65 to 84
years with dementia is expected to double and the num-
ber of people 85 years or older will more than quadru-
ple [2]. Consequently, the number of people living with
dementia is anticipated to rise rapidly. It is forecast that
* Correspondence: Karen.Mate@newcastle.edu.au
1School of Medicine and Population Health, University of Newcastle,
Newcastle, Australia 2308
Full list of author information is available at the end of the article
Pond et al. BMC Family Practice 2012, 13:12
http://www.biomedcentral.com/1471-2296/13/12
© 2012 Pond et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.almost 1 million Australians will suffer from dementia
by 2050, up from 250,000 in 2009 [1].
Dementia is associated with substantial economic,
social and emotional burden. The disease is costly in
terms of the need for support services whether sufferers
live at home or in residential aged care, as well as in
terms of lost productivity for carers and people living
with dementia [3]. The 2010 Intergenerational Report
estimates that Australian Government spending on aged
care will increase from 0.8 per cent of GDP in 2010 to
1.8 per cent by 2050 [2]. In addition to the effect of
dementia on the public and private purse, the emotional
suffering both of those with the disease and of their
families should not be overlooked.
The role of the GP in identifying and managing dementia
General practitioners (GPs) appear well positioned as
the first point of contact for older persons seeking
health care, including those living with dementia. In the
decade between the 2000 and 2010, the number of
patients aged under 45 years seen annually by GPs
increased by 190,000, whereas the number of patients
aged 45 years and over increased by 16 million [4].
Twenty-eight percent of the 98,800 encounters recorded
by the annual Bettering the Evaluation And Care of
Health (BEACH) survey of GP consultations from April
2009 to March 2010 were with patients aged 65 and
over [5].
General practitioners often make the diagnosis of
dementia some considerable time into the course of the
disease [6,7]. However, earlier recognition of symptoms
can allow reversible causes of cognitive decline to be
addressed and identification and management of co-
morbidities (e.g. depression). An early diagnosis also
allows patients time to plan for the future (e.g. prepare
wills, appoint enduring powers of attorney and guar-
dians, prepare advance directives) while they are still
competent to do so. Referral can be made to appropriate
support services and diagnostic centres for further
assessment and/or diagnostic confirmation. Anti-demen-
t i am e d i c a t i o nt h a tm a ys l o wt h ec o u r s eo fc o g n i t i v e
decline may be trialled. Education for patients and
families, along with peer services and support groups,
m a yh e l pt h e mu n d e r s t a n da nd cope with the challen-
ging symptoms of dementia. The support role is particu-
larly stressful [8] and such assistance might reduce
support person morbidity such as depression, and pre-
pare them for maintaining people with dementia at
home longer [9].
General practitioners often fail to identify dementia
early in the course of the disease and also adhere poorly
to published dementia guidelines [10,11]. They often fail
to exclude other possible causes of cognitive impair-
ment, including physical illnesses, medications and
depression [10]; are slow to communicate the diagnosis
to patients and carers [12,13]; and fail to refer people on
to services, support groups, memory clinics or other
specialist resources [10].
Addressing barriers to diagnosis and guideline adherence
Both qualitative and quantitative research suggests a
range of reasons for late diagnosis and otherwise poor
adherence to guidelines by GPs [14]. The barriers speci-
fically addressed in this study are the limited time for
consultation [15], lack of relevant knowledge [16] and
attitudinal factors [13,17]. The GPCOG is a brief screen-
ing test developed and refined by team members to
address the time constraints in general practice consul-
tations [18]. The Australian Care of Patients with
Dementia in General Practice Guidelines [19] were
developed and trialled in consultation with GPs to assist
them in the management of dementia. These guidelines
form the basis for the education used in this study. The
reluctance amongst GPs to diagnose a disease which
lacks a known cure and causes immense suffering to
those who have it and their families [13,17] is also
addressed in the educational intervention.
Screening vs case finding as a means of identifying
dementia
In general, medical advisory groups and policy makers
recommend case finding (further testing only for those
who are perceived by the GP as having symptoms suggest-
ing possible dementia) rather than broadly screening per-
sons over a certain age for dementia [20,21]. It is thought
that screening in this low prevalence population would
result in false positives, causing distress to the patient and
their support person, as well as being a burden to the
healthcare system. Other guidelines have withheld judg-
ment as they claim insufficient evidence for or against
screening [21,22]. This study will compare screening and
case finding approaches to identifying dementia.
Rationale for the educational intervention
This trial addresses the problems outlined above with an
interactive educational intervention for GPs, which is
described in detail below. The education includes visits
by a peer health professional educator and an audit with
feedback. The small positive effects of educational meet-
ings [23] can be improved if they are interactive [24];
outreach visits have shown promise in modifying the
behaviour of professionals [25]; and audit and feedback
has been shown to result in modest improvements in
outcomes [23,26].
Aims of the study
1. Compared to a GP group which does not receive peer
delivered education, to examine whether training in and
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information (see The Intervention section below)
improves:
i. GP identification (diagnosis) of dementia
ii. Distinction by GPs between dementia and other
diseases, including depression (hereafter termed “differ-
ential diagnosis”)
iii. GP elimination of reversible causes of cognitive
impairment
iv. Active management of dementia by GPs as evi-
denced by increased referral to appropriate services, to
Alzheimer’s Australia and/or to medical specialists for
memory problems where indicated.
Outcomes for consumers and their support people in
terms of quality of life (primary outcome), depression
(primary outcome), satisfaction with care, and access to
Alzheimer’s Australia, appropriate services or specialists
when indicated.
2. To determine whether a screening or a case finding
approach to dementia results in:
i. better outcomes for people with dementia and their
carers
ii. a more acceptable process for consumers, support
people and GPs
3. o test the psychometric properties of the GPCOG
including inter-rater reliability, test-retest reliability and
comparison with the MMSE..
Methods/Design
Study Design
The trial is a cluster randomised study (summarised in
Figure 1). Practices allocated to the Intervention group
will receive two dementia related educational detailing
visits from a peer GP or a nurse, and complete three
audits with feedback. Waitlist practices will complete
three audits without feedback and will be mailed
RACGP Dementia Guidelines (including the GPCOG) at
12 months.
Setting
Recruitment will occur across 5 sites: Newcastle (NSW),
Sydney (NSW), Melbourne (Victoria), Adelaide (South
Australia) and Bendigo (Victoria). Sydney, Melbourne
and Adelaide are state capital cities of more than a mil-
lion people each, Newcastle is a regional centre of
around 300,000 people and Bendigo is a smaller centre
of just under 100,000 people with some smaller sur-
rounding towns.
Recruitment of participants
GPs
With the exception of Bendigo (which will also include
nearby towns as noted above) each site will generate a
list of possible GP practices within 30 km of the site
headquarters based on lists provided by the local Divi-
sion of General Practice. Practices will be allocated a
random approach order, and will be contacted via
phone initially. GPs who express an interest in participa-
tion will be visited in order for the study to be
explained. Basic demographics will be collected at this
visit, from those GPs that agree to participate. It is not
expected that all the GPs in a practice will participate.
When one or more GPs in a practice consent, the prac-
tice as a whole will be allocated to either the interven-
tion or waitlist group. Randomisation will occur at a
practice level in order to avoid contamination from
patients visiting several GPs who had been randomised
to different arms within a single practice.
Randomisation will follow procedures outlined in the
CONSORT statement [27]. Practices will be allocated in
a ratio of 2:1 to the Intervention or Waitlist group,
using an allocation schedule provided independent of
t h es t u d yt e a m ,b yt h eC e n t r ef o rE p i d e m i o l o g ya n d
Biostatistics at the University of Newcastle. The rando-
misation code has been developed using a computer
random number generator to select random permuted
blocks. Block lengths of 3 or 6 will be varied randomly.
Practices will be stratified by site, and by size of practice
as either standard or large (large = more than 7 GPs
working in the practice). The intervention group will be
kept at twice the size of the waitlist group in order to
have sufficient power to compare the effects administer-
ing the GPCOG on case finding versus screening
patients (see explanation below).
Inclusion criteria for GPs/practices
￿ Located within 30 kilometres of recruitment centre
(with the exception of Bendigo, a rural town)
￿ Consent to participate in study
￿ Have patients on a computerised database
￿ Have patients aged 75 years and over and living in
the community
￿ Consent to being randomised to either intervention
waitlist group.
Exclusion criteria for GPs/practices
￿ Involved in project development
￿ Does not meet inclusion criteria
Patients and support persons
Patients will be recruited by a mail out from each con-
senting GP to all eligible patients on their database.
Patient participants will return their consent in reply
paid envelopes to the study centre. Patients will be
interviewed by study personnel blind to the group allo-
cation of the patient and their GP. For patients scoring
in the dementia range on the CAMCOG instrument
(described below), the interviewer will request that they
nominate a support person, if available, to take part in
the study. Nominated support people will be given a
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the study.
Inclusion criteria for patients:
￿ Aged 75 years or over
￿ Listed on participating GPs’ databases
￿ Visited recruited GPs within the last 24 months
￿ Consent to a home visit or surgery visit by project
staff
Figure 1 Summary of recruitment, randomization and study design.
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Inclusion criteria for support persons:
￿ Identified as a carer or support person by a patient
scoring in dementia range on CAMCOG instrument
￿ Prior consent from the person with dementia for
his/her carer to participate in the study
￿ Speak and understand English
￿ C o n s e n tt oah o m ev i s i to rs u r g e r yv i s i tb yt h ep r o -
ject staff.
Exclusion criteria for patients:
￿ Parkinson’s disease, multiple sclerosis, motor neuron
disease or central nervous system inflammation
￿ Psychotic symptoms prior to recruitment
￿ Developmental disability
￿ Insufficient English to complete a psychometric
assessment (judged by interviewer)
￿ Progressive malignancy
￿ Substance abuse
￿ Deemed too sick to complete study by the GP
￿ Lives in a residential aged care facility at entry to the
study
￿ Does not meet inclusion criteria
￿ Valid and informed consent cannot be obtained
from the person involved and they do not have a person
responsible for them.
Exclusion criteria for support persons:
￿ Insufficient English to complete testing (judged by
the interviewer)
￿ Non-consenting patient-participant
￿ Does not consent to a home visit or surgery visit by
the project staff.
￿ Too unwell to participate
￿ De not meet inclusion criteria.
Case finding and screening
“Case finding” patients will be identified during the
patient interview using the following 4 questions:
1. Do you have any complaints about your memory?
2. Have you mentioned these to you GP?
3. If not, have you been intending to tell your GP?
4. Have you sought treatment or taken any remedies
such as herbal medications or vitamins specifically for
you memory? Please give details.
If questions 2, 3 or 4 are answered in the affirmative,
the patient will be considered as a “case finding” patient.
Patients identified as having possible or probable demen-
tia on the GP baseline audit will also be considered as a
“case finding” patient. All other patients will be identified
as “screening” patients - that is, patients who would not
receive a cognitive function test unless the GP decided to
screen all patients aged over a certain age.
The intervention
All GPs will audit their consenting patients for demen-
tia, and complete a supplementary audit indicating diag-
nostic evaluation and management for patients they
consider to have dementia. This will occur at three time
points during the study: baseline, 12 months and 24
months. Intervention GPs will receive education as
described below. The rationale for the educational inter-
vention is described in the Background section above.
Intervention GPs
Intervention GPs will participate in two visits at their
surgery with a peer medical or nurse educator. At the
first visit (after completion of the baseline audit), GPs
will be taught how to use the GPCOG screening instru-
ment (described below), and will be given information
about dementia diagnosis, diagnostic workup and man-
agement according to strategies incorporated in the
RACGP Consensus Guidelines for the care of Patients
with Early Dementia (hereafter called the RACGP
Dementia Guidelines) [19]. Negative attitudes about
making a dementia diagnosis will be explored and
addressed. With the GPs’ consent, these sessions will be
recorded for qualitative analysis. The structural issue of
lack of time in the GP consultation will be addressed by
teaching the GPs to use a brief screening instrument
and by discussing potential methods of obtaining assis-
tance from the practice nurse. A business case regarding
the cost effectiveness of dementia assessment will also
be presented. All intervention GPs will be provided with
support materials and the RACGP Dementia Guidelines
at this visit. These GPs will receive a second detailing
visit after completion of their 12 month audit. At the
second visit, intervention GPs will receive written and
verbal feedback about their baseline audit in the light of
individual patient results from the home assessment.
As the study is being conducted across five sites, a
number of different peer educators will be used. All
educators will undergo a training program either face-
to-face or via teleconference to familiarise them with
the educational package developed for intervention GPs.
The package consists of a slide presentation that will be
delivered by educators via laptop computer, and hard-
copy support materials that will be supplied to the GPs.
Waitlist GPs
Waitlist GPs will complete the audits as per Figure 1.
No feedback will be given to waitlist GPs during the
c o u r s eo ft h es t u d y .T h e yw i l lb em a i l e dt h eR A C G P
Dementia Guidelines after completion of the 12 month
audit. Apart from administrative phone calls to obtain
the audits, waitlist GPs will have no other contact with
the study team.
Pond et al. BMC Family Practice 2012, 13:12
http://www.biomedcentral.com/1471-2296/13/12
Page 5 of 9Research instruments
The following instruments will be used be used as part
of the patient and/or carer assessments:
The GPCOG
The GPCOG [18,28] is a simple dementia-screening
instrument, translated into a number of languages and is
freely available on the internet http://www.gpcog.com.au.
The refined version of the GPCOG has not been trialed in
a large random sample of GP patients. It is considered
superior to other screening instruments such as the
MMSE [29] because of its brevity, psychometric properties
and its use of informant report in borderline cases [28].
The CAMCOG
The CAMCOG is a subsection of the CAMDEX instru-
ment, which has been validated in the UK [30]. The
CAMCOG has the MMSE embedded in it and, thus,
allows comparison between the GPCOG and the
MMSE. The CAMCOG was used in our previous study
to validate the original version of the GPCOG [18].
The Geriatric Depression Scale
The Geriatric Depression Scale (GDS) has been well
validated and widely used in Primary Health Care
research [31]. The GDS-15 will be used to limit the
time imposed on participants.
The WHOQOL-BREF
The WHOQOL-BREF is a widely used quality of life
instrument [32], which has been validated for use in the
Australian population [33].
The Beck Depression Inventory
The Beck Depression Inventory [34] has been widely
used in the general population to screen for depression.
The General Practice Assessment Questionnaire
The General Practice Assessment Questionnaire
(GPAQ) will be used to ascertain the patients’ support
persons’ satisfaction with their care from their GP over
the previous 12 months. The GPAQ is very widely used
in the UK as part of the GP quality outcomes frame-
work, and has been shown to be acceptable, reliable and
have an interpretable factor structure [35].
Activities of Daily Living (ADL)
The Lawton and Brody ADL Questionnaire [36] will be
used to measure the functional abilities of patients who
score in the dementia range on the CAMCOG instrument.
This 13-item questionnaire designed for use in elderly
patients with neurological disorders, measures both instru-
mental (eg ability to manage finances, medications) and
basic (eg toileting, grooming) ADL. It will be completed
by the support person (if available) or the patient.
Data collection
Patient assessment
The research nurse will use a laptop computer to collect
demographic data from all consenting patients and to
administer the GPGOG, CAMCOG, GDS, WHOQOL-
BREF, GPAQ and ADL (for patients in CAMCOG
dementia range only). Patients will be asked about any
memory-related services accessed, referral to Alzhei-
mer’s Australia, and referral to a specialist for memory
problems. The research nurse will compile a list of all
prescription and over the counter medications currently
used by the patient, so that medication can be excluded
as a cause of cognitive impairment. Complementary and
alternative medicines will be included. In addition the
nurse will perform a “75 + Health Assessment” rebate-
able under the Australian Medicare system on eligible
patients where this has been requested by the GP.
These data will not be used by the study, but are
returned to the GP for his or her use. This part of the
assessment is a provided as a service to the GP. Brief
questions used in our previous research will be used to
measure the acceptability of the interview process. We
will ask patients to send answers back in a reply-paid
envelope, to avoid bias due to the presence of the nurse.
At the completion of the assessment the nurse will hand
the patient a sealed envelope. In the case of patients in
the intervention group, it will direct the patient to
obtain an appointment with his/her GP as soon as pos-
sible to follow up on the 75+ Health Assessment and to
have the GPCOG re-administered. In the case of
patients in the waitlist group, it will suggest a follow up
for the 75 Plus Health Assessment only. Patients will be
reassessed using the same instruments at 12 and 24
months after baseline interviews.
Support person assessment
The research nurse will use a laptop computer to collect
demographic data from consenting support persons and
to administer the WHOQOL-BREF, BDI and GPAQ.
Information regarding services accessed and accept-
ability of the interview process will be collected as
described above for patients. Patients will be reassessed
using the same instruments at 12 and 24 months after
baseline interviews.
GP audit
GPs will be sent a list of their participating patients by
fax or email. They will be asked to confirm each
patient’s eligibility for the study and to provide their
clinical judgement in relation to each patient’s dementia
status using one of four options: No Dementia, Possible
Dementia, Probable Dementia or Definite Dementia.
GPs will be asked to complete a supplementary audit
for any patients with possible, probable or definite
dementia to gather data on differential diagnosis (e.g
depression), memory-related tests and investigations
performed (i.e. paper and pencil test; pathology; radiol-
ogy) and referrals to services and specialists. GPs will
return their completed audit forms to local project offi-
cer via mail, fax or email. GPs will complete audits at
baseline, 12 and 24 months.
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Primary outcome measures related to the first aim (col-
lected at baseline, 12 months and 24 months) are:
1. World Health Organization Quality of Life-Bref
Scale (WHOQOL-BREF) score for patients
2. Geriatric Depression Scale score for patients
Secondary outcome measures related to the first aim
(collected at baseline, 12 months and 24 months) are:
1. World Health Organization Quality of Life-Bref
Scale (WHOQOL BREF) for carers
2. Beck Depression Inventory score for carers
3. Agreement of GP audit for dementia with CAM-
COG instrument
4. GP differential diagnosis for dementia
5. GP identification and treatment of reversible causes
of dementia 6.GP dementia related referrals made
7. General Practice Assessment Questionnaire score
8. Acceptability of the process scale score
9. Services accessed
To meet the second aim of the study, screening and
case finding groups (as defined above) will be compared
on primary and secondary outcome measures 1 and 2 as
listed above. The GPCOG score will be compared with
the gold standard of the CAMCOG score to address the
third aim of the study. The performance of the GPCOG
against the CAMCOG will also be compared with that
of the MMSE against the CAMCOG, as the MMSE is
widely used to screen for dementia.
Adverse events
Research nurses will report any subjects that they are
concerned about to their local academic GP associated
with the project. The GP will decide upon a course of
action, up to and including reporting the matter to the
subject’s own GP (with subject permission). Nurses will
cease interviewing subjects who report feeling tired or
uncomfortable during the interview. The subject will be
given the option of completing the interview at a later
time, using only the data collected to that point, or
withdrawing from the study.
Sample size
It was calculated that 45 patients with dementia in each
group (Waitlist and Intervention) would give a power of
0.9 to detect a 7% difference between the change in pre
and post scores on any of the four domain scales of the
WHOQOL-BREF with a type 1 error of .05. The popu-
lation standard deviation used is 18.5 [32] and the Pear-
son correlation coefficient between the pre and post
scores for both groups is assumed to be 0.7, based on
pilot data available from the University of Melbourne.
The hierarchical nature of the study design will prob-
ably lead to some within cluster correlations and the
greatest impact of this is likely to be associated with
patients clustered within a GP practice. Clustering
within each GP may be discounted, as it is anticipated
that most GPs will have less than five patients with
dementia in this study. Assuming an intra-class correla-
tion coefficient of 0.05 and an average cluster size of 5
patients with dementia in a practice, this gives a design
effect of 1.45 and a total sample size of 54 patients per
group. We will therefore allow for 56 patients with
dementia in the waitlist group and 112 in the interven-
tion group to allow for comparison of outcomes
between the waitlist and intervention groups overall.
This sample size also allows comparison of “case find-
ing” and “screening” patients and their support persons
within the group. It is assumed that about 50% of parti-
cipants will be screening and 50% case finding. Thus, we
aim to recruit 168 participants with dementia overall.
Based on a dementia prevalence of approximately 10%
in over 75 year old Australians [37], we aim to recruit a
total of 2,000 participants.
For the GDS, following the same set of assumptions
a n da p p r o a c ha sf o rt h eW H OQ O L - B R E F( p o w e r ,t y p e
1 error and correlations), 45 patients in both the Inter-
vention and Waitlist groups would allow detection of an
average difference in the change in pre and post scores
of 0.9 points on the 15 point GDS, using a standard
deviation of 2.39 [28]. The cluster effect would be the
same as for the WHOQOL-BREF.
For an estimate of test re-test reliability on the
GPCOG a sample size of 100 will be used to ensure the
correlation is estimated to a reasonable precision. The
95% confidence interval for a Pearson correlation of 0.9
would be [0.86, 0.93] and for a correlation of 0.80 [0.73,
0.85].
Study drop outs/withdrawals
Subjects
We aim to recruit 2000 subjects, based on a dementia
prevalence rate of 10% in the Australian population
aged 75 years and over [37]. We anticipate a 10% drop
out per annum, giving us 180 subjects with dementia at
the 12 month mark, and 162 at 24 months, with a small
number of incident cases.
GPs
We do not anticipate a high drop-out rate of GPs, as the
demands on GPs are not onerous. As patients are con-
sented separately to GPs, patients can continue even if
their GPs withdraw from the study.
Statistical analyses
All surveys collected on laptop computers will be down-
loaded to a central database. Where necessary in the
analysis, the longitudinal and hierarchical/cluster nature
of the study design will be taken into account using
mixed effects models and other appropriate methods
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treat. Analyses will address the following questions:
Do GPs trained in the use of a screening instrument detect
dementia better?
Detection rates of GPs trained in using the GPCOG (the
Intervention group) will be compared with detection
rates of Waitlist GPs against the ‘gold standard’ of the
CAMCOG.
Do GPs trained in screening and management distinguish
dementia from other conditions, particularly depression,
compared with a waitlist group?
Differential diagnoses (particularly of depression), of the
Intervention group will be compared with those of the
Waitlist group. Misclassification rates of the GPs in the
Intervention group will be compared with those in the
waitlist group.
Do GPs trained in screening and management adhere to
the guidelines?
Outcomes measured will include identification of rever-
sible causes of dementia, tests ordered and referral pat-
terns to specialists, support services and Alzheimer’s
Australia, as suggested in the guidelines.
Do GPs trained in screening and management provide
better health outcomes?
Outcomes of Intervention and Waitlist groups will be
compared at twelve months, for both patients and their
carers (quality of life, depression, satisfaction with care,
services accessed)
Do subjects with and without dementia and support
persons find the screening acceptable?
All subjects and support persons will be asked to rate
the acceptability of the screening instrument and proce-
dures. Descriptive analysis will be performed. Case find-
ing and screening groups will be compared.
Do GPs find the process acceptable?
GPs will be asked to rate the acceptability of the
GPCOG and the Management Guidelines. Descriptive
data will be reported.
Does case finding or screening produce better results?
Within the Intervention group, the patient outcomes for
the group with memory complaints or identified by the
GP as having possible or probable dementia (case find-
ing group) will be compared with outcomes for the
group without memory complaints or identified memory
problems (screening group). Acceptability of the process
and satisfaction with care will be particularly examined,
both from a quantitative and a qualitative point of view.
The performance of the GPCOG in the case finding and
screening groups will be compared. In particular positive
predictive value, negative predictive value and misclassi-
fication rates will be compared. GP audits will be exam-
ined to determine how many patients in each group
would have a missed diagnosis of dementia if the
GPCOG had not been administered.
Test parameters of the GPCOG
The GPCOG will be compared with the DSM diagnosis
derived from the CAMCOG as a ‘gold standard’,a n d
sensitivity, specificity, positive predictive value, negative
predictive value and misclassification rate will be calcu-
lated. ROC curve analysis will be employed to examine
the discrimination ability of the GPCOG test (i.e. ability
to detect dementia) relative to MMSE. This is important
as the MMSE is now commonly used in General Prac-
tice. GPCOG test-re-test and inter-rater reliability
(between the nurse and the GP) will be calculated, using
the kappa coefficient and intra-class correlation
coefficient.
Missing data
In the case of data missing from the study question-
naires, the questionnaires will be handled as suggested
in the literature for that questionnaire. This varies from
questionnaire to questionnaire.
Steering group
The project is being overseen by a group consisting of
the chief investigators, associate investigators and the
project manager. This group will meet two to three
times a year by teleconference and face to face. Day to
day management will be undertaken by monthly project
officer teleconferences.
Ethics
Ethics approval was sought and granted initially from
the Newcastle University Human Research Ethics Com-
mittee (Approval No. H-151-1205), and following this,
from the appropriate Ethics Committees at each site.
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